Pharmacogenetics in the Treatment of Chronic Lymphocytic Leukemia: What Does the Future Hold?

References

• Hallek M . Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment . Am. J. Hematol.88 ( 9 ), 803 – 816 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hallek M , FischerK , Fingerle-RowsonGet al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase III trial . Lancet376 ( 9747 ), 1164 – 1174 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Fischer K , CramerP , BuschRet al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group . J. Clin. Oncol.30 ( 26 ), 3209 – 3216 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Foa R , Del GiudiceI , CuneoAet al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients . Am. J. Hematol.89 ( 5 ), 480 – 486 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lotfi K , KarlssonK , FyrbergAet al. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia . Biochem. Pharmacol.71 ( 6 ), 882 – 890 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rivero A , RapadoI , TomasJFet al. Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma . Leukemia Res.35 ( 4 ), 431 – 437 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Errasti-Murugarren E , Pastor-AngladaM . Drug transporter pharmacogenetics in nucleoside-based therapies . Pharmacogenomics11 ( 6 ), 809 – 841 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Helsby NA , TingleMD . Which CYP2B6 variants have functional consequences for cyclophosphamide bioactivation?Drug Metab. Dispos.40 ( 3 ), 635 – 637 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lang T , KleinK , FischerJet al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver . Pharmacogenetics11 ( 5 ), 399 – 415 ( 2001 ).
   PubMedGoogle Scholar
• Johnson GG , LinK , CoxTFet al. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia . Blood122 ( 26 ), 4253 – 4258 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bezombes C , FournieJJ , LaurentG . Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives . Mol. Cancer Res.9 ( 11 ), 1435 – 1442 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dornan D , SpleissO , YehRFet al. Effect of FCGR2A and FCGR3A variants on CLL outcome . Blood116 ( 20 ), 4212 – 4222 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Di Gaetano N , CitteraE , NotaRet al. Complement activation determines the therapeutic activity of rituximab in vivo . J. Immunol.171 ( 3 ), 1581 – 1587 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Racila E , LinkBK , WengWKet al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma . Clin. Cancer Res.14 ( 20 ), 6697 – 6703 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Pandya U , SrivastavaSK , SinghalSSet al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil . Biochem. Biophys. Res. Commun.278 ( 1 ), 258 – 262 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Teichert J , BaumannF , ChaoQet al. Characterization of two Phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride . Cancer Chemother. Pharmacol.59 ( 6 ), 759 – 770 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zhou SF , WangB , YangLP , LiuJP . Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 . Drug Metabolism Rev.42 ( 2 ), 268 – 354 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hon YY , JuskoWJ , SpratlinVE , JannMW . Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism . J. Clin. Pharmacol.46 ( 4 ), 408 – 417 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Byrd JC , FurmanRR , CoutreSEet al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia . N. Engl. J. Med.369 ( 1 ), 32 – 42 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Furman RR , SharmanJP , CoutreSEet al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia . N. Engl. J. Med.370 ( 11 ), 997 – 1007 ( 2014 ).
   PubMed Web of Science ®Google Scholar